化学
BRD4
溴尿嘧啶
三环
药理学
黑色素瘤
虚拟筛选
药代动力学
衍生工具(金融)
药物发现
表观遗传学
立体化学
癌症研究
生物化学
医学
基因
金融经济学
经济
作者
Yuhei Horai,Naoki Suda,Shinsuke Uchihashi,Mayako Katakuse,Tomomi Shigeno,Takashige Hirano,Junichi Takahara,Tomoyuki Fujita,Yohei Mukoyama,Yuji Haga
标识
DOI:10.1016/j.bmc.2023.117461
摘要
The epigenetic regulation of the protein bromodomain-containing protein 4 (BRD4) has emerged as a compelling target for cancer treatment. In this study, we outline the discovery of a novel BRD4 inhibitor for melanoma therapy. Our initial finding was that benzimidazole derivative 1, sourced from our library, was a powerful BRD4 inhibitor. However, it exhibited a poor pharmacokinetic (PK) profile. To address this, we conducted a scaffold-hopping procedure with derivative 1, which resulted in the creation of benzimidazolinone derivative 5. This new derivative displayed an improved PK profile. To further enhance the BRD4 inhibitory activity, we attempted to introduce hydrogen bond acceptors. This indeed improved the activity, but at the cost of decreased membrane permeability. Our search for a potent inhibitor with desirable permeability led to the development of tricyclic 18. This compound demonstrated powerful inhibitory activity and a favorable PK profile. More significantly, tricyclic 18 showed antitumor efficacy in a mouse melanoma xenograft model, suggesting that it holds potential as a therapeutic agent for melanoma treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI